Sophie Graff

Dr. Sophie Graff


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2020 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
FSFlorence Schleich
Florence Schleich
SGSophie Graff
Sophie Graff
HNHaleh Nekoee
Haleh Nekoee
CMCatherine Moermans
Catherine Moermans
MHMonique Henket
Monique Henket
RLRenaud Louis
Renaud Louis

1 June 2019 in Respiratory Medicine
Verified
Journal Article
Closed access
SGSophie Graff
Sophie Graff
SDSophie Demarche
Sophie Demarche
MHMonique Henket
Monique Henket
VPVirginie Paulus
Virginie Paulus
RLRenaud Louis
Renaud Louis
FSFlorence Schleich
Florence Schleich

1 December 2020 in Respiratory Medicine
Verified
Journal Article
Closed access
SGSophie Graff
Sophie Graff
NBNoëmie Bricmont
Noëmie Bricmont
CMCatherine Moermans
Catherine Moermans
MHMonique Henket
Monique Henket
VPVirginie Paulus
Virginie Paulus
FSFlorence Schleich
Florence Schleich

1 February 2022 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
SGSophie Graff
Sophie Graff
GBGuy Brusselle
Guy Brusselle
SHShane Hanon
Shane Hanon
CSCarine Sohy
Carine Sohy
LDLieven Dupont
Lieven Dupont
FSFlorence Schleich
Florence Schleich

12 August 2020 in Respiratory Research
Verified
Journal Article
Open access
PDF file
SGSophie Graff
Sophie Graff
SVS. Vanwynsberghe
S. Vanwynsberghe
GBG. Brusselle
G. Brusselle
SHS. Hanon
S. Hanon
CSC. Sohy
C. Sohy
FSF. N. Schleich
F. N. Schleich
Background: Severe asthma (SA) may require frequent courses or chronic use of oral corticosteroids (OCS), inducing many known side effects and complications. Therefore, it is important to identify risk factors of chronic use of OCS in SA, considering the heterogeneity of clinical and inflammatory asthma phenotypes. Another aim of the present analysis is to characterize a subpopulation of severe asthmatics, in whom blood eosinophil counts (BEC) remain elevated despite chronic OCS treatment.Methods: In a cross-sectional analysis of 982 SA patients enrolled in the Belgian Severe Asthma Registry (BSAR) between March 2009 and February 2019, we investigated the characteristics of the OCS treated patients with special attention to their inflammatory profile.Results: At enrollment, 211 (21%) SA patients were taking maintenance OCS (median dose: 8 [IQR: 5–10]) mg prednisone equivalent). BEC was high (> 400/mm3) in 44% of the OCS treated population. Multivariable logistic regression analysis showed that risk factors for chronic use of OCS in SA were late-onset asthma (i.e. age of onset > 40 yr), frequent exacerbations (i.e. ≥2 exacerbations in the previous year) and non-atopic asthma. Late-onset asthma was also a predictor for persistently high BEC in OCS treated SA patients.Conclusion: These data showed a significant association between a persistently high BEC and late-onset asthma in OCS treated SA patients. Whether it is poor compliance to treatment or corticosteroid insensitivity the reasons for this association warrants further investigation.

9 March 2023 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
JKJohannes A. Kroes
Johannes A. Kroes
RARafael Alfonso-Cristancho
Rafael Alfonso-Cristancho
ABAruna T. Bansal
Aruna T. Bansal
EBEmmanuelle Berret
Emmanuelle Berret
KBKristina Bieksiene
Kristina Bieksiene
ABAnneke Ten Brinke
Anneke Ten Brinke
Background: An objective of the Severe Heterogeneous Asthma Registry, Patient-centered (SHARP) is to produce real-world evidence on a pan-European scale by linking nonstandardised, patient-level registry data. Mepolizumab has shown clinical efficacy in randomised controlled trials and prospective real-world studies and could therefore serve as a proof of principle for this novel approach. The aim of the present study was to harmonise data from 10 national severe asthma registries and characterise patients receiving mepolizumab, assess its effectiveness on annual exacerbations and maintenance oral glucocorticoid (OCS) use, and evaluate treatment patterns. Methods: In this observational cohort study, registry data (5871 patients) were extracted for harmonisation. Where harmonisation was possible, patients who initiated mepolizumab between 1 January 2016 and 31 December 2021 were examined. Changes of a 12-month (range 11–18 months) period in frequent (two or more) exacerbations, maintenance OCS use and dose were analysed in a privacy-preserving manner using meta-analysis of generalised estimating equation parameters. Periods before and during the coronavirus disease 2019 pandemic were analysed separately. Results: In 912 patients who fulfilled selection criteria, mepolizumab significantly reduced frequent exacerbations (OR 0.18, 95% CI 0.13–0.25), maintenance OCS use (OR 0.75, 95% CI 0.61–0.92) and dose (mean −3.93 mg·day −1 , 95% CI −5.24–2.62 mg·day −1 ) in the pre-pandemic group, with similar trends in the pandemic group. Marked heterogeneity was observed between registries in patient characteristics and mepolizumab treatment patterns. Conclusions: By harmonising patient-level registry data and applying federated analysis, SHARP demonstrated the real-world effectiveness of mepolizumab on asthma exacerbations and maintenance OCS use in severe asthma patients across Europe, consistent with previous evidence. This paves the way for future pan-European real-world severe asthma studies using patient-level data in a privacy-proof manner.